← Back to Search

Device

tDCS for Alzheimer's Disease (NICE-AD Trial)

N/A
Recruiting
Led By Joe Verghese, MD
Research Sponsored by Albert Einstein College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to speak and understand English or Spanish at a level sufficient to undergo the study procedures and testing protocols
AD diagnosed by neurologists or geriatricians at our dementia and geriatric clinical sites
Must not have
History of head trauma, seizures, brain surgery, stroke, or cancer affecting head
Unstable medical or major psychiatric illnesses or unstable treatments for medical or major psychiatric illnesses
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, at 6 months (immediately after the 6-month intervention), at 7 months (1 month post-intervention) and 9-months (3 months post-intervention).

Summary

This trial will determine if transcranial Direct Current Stimulation (tDCS) can improve cognitive performance and symptoms in patients with mild to moderate Alzheimer's Disease (AD), and reduce burden associated with this debilitating illness.

Who is the study for?
This trial is for people aged 60 or older with mild to moderate Alzheimer's Disease, diagnosed by specialists. Participants must be stable on dementia medications if any, speak English or Spanish well enough for study procedures, and agree to an MRI scan. Those with unstable health conditions, skin issues where electrodes are placed, head trauma history, metal implants in the head/neck, or involved in other studies can't join.
What is being tested?
The study tests a tDCS device delivering either active or sham (fake) stimulation to the brain's dorsolateral prefrontal cortex at home. It aims to see if this treatment improves cognitive performance and symptoms over six months and affects neuroplasticity markers in patients with Alzheimer's.
What are the potential side effects?
tDCS may cause discomfort at the electrode site on the scalp, itching under the electrodes during stimulation sessions, headache after sessions end, fatigue or insomnia following treatments. Serious side effects are rare but could include seizures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can speak and understand English or Spanish well enough for medical procedures.
Select...
I have been diagnosed with Alzheimer's disease by a specialist.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of head trauma, seizures, brain surgery, stroke, or cancer affecting my head.
Select...
My medical and mental health conditions are stable.
Select...
I have skin issues where electrodes might be placed.
Select...
I have metal implants in my head or neck.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, at 6 months (immediately after the 6-month intervention)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, at 6 months (immediately after the 6-month intervention) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Global Cognitive Performance
Secondary study objectives
Depressive Symptoms
Executive control/spatial selective attention
Functional Neuroplasticity - Flanker Interference Task
+5 more
Other study objectives
Durability of Global Cognitive Performance
Structural Neuroplasticity

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active tDCSExperimental Treatment1 Intervention
The active tDCS will involve 30-minutes of direct current at intensity of 2 milliamperes (mA).
Group II: Sham tDCSPlacebo Group1 Intervention
Sham stimulation consists of the direct current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining application period.

Find a Location

Who is running the clinical trial?

MJHS Institute for Innovation in Palliative CareOTHER
5 Previous Clinical Trials
1,603 Total Patients Enrolled
Albert Einstein College of MedicineLead Sponsor
296 Previous Clinical Trials
11,688,917 Total Patients Enrolled
Joe Verghese, MDPrincipal InvestigatorStony Brook University
2 Previous Clinical Trials
6,983 Total Patients Enrolled

Media Library

tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS (Device) Clinical Trial Eligibility Overview. Trial Name: NCT04404153 — N/A
Alzheimer's Disease Research Study Groups: Sham tDCS, Active tDCS
Alzheimer's Disease Clinical Trial 2023: tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS Highlights & Side Effects. Trial Name: NCT04404153 — N/A
tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04404153 — N/A
~14 spots leftby Jul 2025